Biofrontera AG: Biofrontera AG resolves on capital increase
17 February 2016 - 3:45AM
Biofrontera AG / Biofrontera AG: Biofrontera AG resolves on
capital increase . Processed and transmitted by NASDAQ OMX
Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
Leverkusen, Germany, February 16, 2016 - The Management Board of
Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with
the approval of the Supervisory Board, to increase the registered
share capital of the Company by up to EUR 2,357,384 from authorized
capital by issuing up to 2,357,384 new no-par registered shares
("New Shares"). The shareholders' subscription right is excluded.
The New Shares were offered to selected institutional investors at
an issue price of EUR 1.90 per New Share, for a total issue price
of EUR 4,479,029.60. All shares were successfully placed
today.
The net proceeds of approx. EUR 4.4 mio will be
used to cover the operational expenses of the Company and the
further development of marketing the Company's main product BF-200
ALA. Currently, BF-200 ALA is approved for the treatment of actinic
keratosis in the EU. With the proceeds from this issue, the Company
intends to support the regulatory approval and commercialization in
the US as well as the extension of the European approval of BF-200
ALA for treatment of basal cell carcinoma.
About Biofrontera
Biofrontera Group (FSE/AIM:
B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical
cosmetics for the care and treatment of skin diseases.
Biofrontera's most important product is Ameluz®, a prescription drug which is approved in
Europe for the treatment of mild and moderate actinic keratosis
(superficial skin cancer) with photodynamic therapy (light
therapy). Biofrontera is the first German pharmaceutical start-up
company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz® to be approved for basal
cell carcinoma and is currently preparing for approval in other
countries, especially in the largest pharmaceutical market in the
world, the United States.
The company also markets the Belixos®
dermatological range of cosmetics. Belixos® products, a cream, a
gel and a scalp tonic, contain combinations of active substances
extracted from plants, relieve itching and redness and are used for
the regenerative care of chronic skin conditions such as atopic
dermatitis or psoriasis. The Belixos® Protect, a daily skincare for
sun-damaged skin, complements this dermo-cosmetic line. All
products are available through Amazon.
The Biofrontera Group was established in 1997 by
Prof. Dr Hermann Lübbert, the Chairman of the company's Management
Board, and has its headquarters in Leverkusen, Germany.
For more information, visit
www.biofrontera.com
This
communication expressly or implicitly contains certain
forward-looking statements concerning the business activities of
Biofrontera AG. These forward-looking statements reflect the
opinion of Biofrontera at the time of this communication and
involve certain known and unknown risks. The actual results
achieved by Biofrontera may differ significantly from future
results or performances which are published in its forward-looking
statements. Biofrontera assumes no responsibility to update its
forward-looking statements.
U.S.
Contact:
The Ruth
Group
Lee Roth (Investors) / Kirsten Thomas (Media)
lroth@theruthgroup.com / kthomas@theruthgroup.com
+1 646-536-7012 / +1 508-280-6592
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Biofrontera AG via Globenewswire
HUG#1986504
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;
Biofrontera (LSE:B8F)
Historical Stock Chart
From Apr 2024 to May 2024
Biofrontera (LSE:B8F)
Historical Stock Chart
From May 2023 to May 2024